secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-031575
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q3 net loss $4.0M; cash $9.8M, funds only through Q1 2023; Phase 3 ADHD trial starts Dec 2022
--------------------------------------------------------------------------------

- Q3 2022 net loss $4.0M vs $15.3M in Q3 2021; cash and equivalents $9.8M, expected to fund only through first quarter 2023.
- Phase 3 adult dose-optimization study for lead ADHD candidate CTx-1301 to commence December 2022; NDA submission targeted H1 2024.
- Executed Master Services Agreement with Societal CDMO to manufacture clinical, registration, and commercial batches of CTx-1301.
- Anxiety candidate CTx-2103 triple-release buspirone achieved solubility targets; clinical program design underway.
- Phase 1/2 bioavailability study for ADHD candidate CTx-1302 (dextroamphetamine) planned for first half 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/0001493152-22-031575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer